Hopes of a coronavirus vaccine mount as three key biotech players make progress

News

Why business should not throw in the towel in the face of COVID-19

“I would like to appeal to all large businesses not to resort to force majeure and stop paying their suppliers and rental commitments , as such practice has a domino effect on all other businesses dependent on that chain,”

SA extends lockdown by two weeks until end April

South Africa's President Cyril Ramaphosa on Thursday evening extended the country's lockdown by two weeks until the...

COVID-19: Trump hold on finances would hurt our work in Africa – WHO.

"If that decision is made it would severely impact our work here in Africa,” says Moeti.

Key Points

  • Over the last 48 hours, three biotech companies, in particular, have been thrust into the spotlight for their promise: BioNTech, CureVac and Moderna.
  • All three of these firms specialize in messenger RNA (mRNA) therapeutics.
  • These mRNA molecules are used to instruct the body to produce its own immune response to fight a range of different diseases.

The race is on to develop an immunization against COVID-19. 

Dozens of companies and public labs around the world are working to develop a vaccine to prevent the spread of the flu-like virus. Over the last 48 hours, three biotech companies, in particular, have been thrust into the spotlight for their promise: BioNTech, CureVac and Moderna.

All three of these firms specialize in messenger RNA (mRNA) therapeutics. These mRNA molecules are used to instruct the body to produce its own immune response to fight a range of different diseases. This type of vaccine can potentially be developed and produced more quickly than traditional vaccines.

Moderna is a Massachusetts-based biotech company working with the U.S. National Institutes of Health (NIH). It kicked off its first trial Monday in Seattle, Washington. 

This is called a “phase one” study and is being conducted by the NIH. Moderna is also preparing for a potential “phase two” study that it would conduct itself. Moderna shares rose 27% in Monday’s trading session.

BioNTech, meanwhile, is a German biotech company which recently announced two strategic partnerships to advance development of a vaccine. It formed a collaboration with Fosun Pharma to advance efforts in China, and with Pfizer to do the same outside China. 

Berenberg bank analysts say they are impressed with the company’s efforts to rapidly enter into an alliance with a top pharma company in China and they view it as an important validation of BioNTech’s mRNA technology platform. 

“BioNTech appears best positioned in the COVID-19 race owing to its diversified mRNA platform, delivery information and manufacturing capacity,” Berenberg said in a research note.

CureVac is an unlisted German company which aims to start testing an experimental vaccine on humans this summer. After reportedly getting caught in the political crossfire between Germany and the U.S., the European Commission pledged 80 billion euros of financial support to help them get a product out in Europe. 

On Monday, CureVac noted it “is working on expanding its manufacturing capacities to be able to provide up to billions of doses for outbreak situations like Covid-19.”

As evidenced by these companies, partnerships are key to developing and manufacturing vaccines for the public. Both public-private partnerships as well as partnerships between the traditional pharmaceutical giants and smaller biotech players can be critical to getting these vaccines from trial to market. 

However, the jury is still out on what type of therapeutic approach will work best. Barclays pharmaceutical research team noted that while mRNA vaccines remain unproven, they are likely to dominate the shorter-term headlines given faster development timelines and rapid early progress. 

Ultimately, the Barclays team believes these novel vaccines are likely to be superseded by more conventional approaches over time.

(Report by Julianna Tatelbaum)

This article was first published on CNBC https://www.cnbc.com/2020/03/17/hopes-of-a-coronavirus-vaccine-mount-as-three-key-biotech-players-make-progress.html and is republished with its permission.

- Advertisement -
- Advertisement -

Featured

COVID-19: Moody’s downgrades Zambia from stable to negative

Africa will tread a tough road ahead as ratings agencies throw its iron fists upon African countries amid the COVID-19 crisis and economic disruptions impact private sector activity in Sub- Saharan Africa. Ridle Markus, Africa Strategist at Absa Corporate and Investment Banking joins CNBC Africa for more.

Subscribe to our newsletter

Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox

Update on Rupert family’s R1bn COVID-19 fund

This week Johann Rupert’s R1billion Sukuma fund had to close doors on desperate small businesses wanting help to fight the impact of COVID-19 lockdowns.

World Bank considers debt relief for Africa to fight COVID-19

The World Bank expects COVID-19 to cost Sub-Saharan Africa up to $79 billion in lost output in 2020, plunging the region into its first recession in a quarter of a century. World Bank’s Chief Economist for Africa, Albert Zeufack joins CNBC Africa for more.

Why China will be least hit by capital exodus from emerging markets

The COVID-19 shock has fuelled the biggest capital outflows from emerging markets on record in the first quarter, and the situation is unlikely to improve for the rest of the year. That’s according to research from the Institute of International Finance. Elina Ribakova, Deputy Chief Economist from the (IFF) Institute of International Finance joins CNBC Africa for more.

I&M Bank Rwanda reduces interest rates by 0.5% to cushion customers from COVID-19

In an attempt to ease the burden of high interest costs on customers affected by the COVID-19 pandemic, I&M Bank Rwanda has reduced their interest rates by 0.5 per cent. CNBC Africa spoke to CEO, Robin Bairstow for more.
- Advertisement -

More Articles Like This

- Advertisement -